HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Breast Cancer Update
00:00
Impact of prior CDK4/6 duration on choices
Hamilton explains how short versus long benefit on CDK4/6 influences moving to endocrine therapy, combos, or chemotherapy.
Play episode from 36:16
Transcript
